We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.54 | -0.83% | 64.79 | 64.30 | 64.85 | 65.53 | 64.33 | 65.51 | 7,822,721 | 05:00:04 |
From May 2019 to May 2024
By Colin Kellaher
Gilead Sciences Inc. (GILD) on Wednesday said it would collaborate with privately held biotechnology company Nurix Therapeutics Inc. to develop new therapies for cancer and other diseases.
Gilead said it will make an upfront payment of $45 million to Nurix, which is working to discover drugs that harness the body's natural process to control protein levels.
San Francisco-based Nurix will also be eligible for up to roughly $2.3 billion in additional milestone payments, along with royalties on product sales, Gilead said.
The Foster City, Calif., biopharmaceutical company said it will have an option to license drug candidates directed to up to five targets resulting from its work with Nurix, which is backed by life-science investors Third Rock Ventures and Column Group.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 19, 2019 09:04 ET (13:04 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
